Transthyretin cardiomyopathy (ATTR-CM): cross-border specialty drug access for international patients

Quick orientation

ATTR cardiomyopathy is increasingly recognized in older adults and patients with otherwise unexplained heart failure with preserved ejection fraction. Wild-type ATTR-CM may affect up to 13 percent of HFpEF patients in some series.

Typical age of onset. Wild-type forms typically diagnosed after age 65; hereditary forms can present earlier.

Severity tiers. Severity is staged by hemodynamics, biomarkers, and functional class. Untreated ATTR-CM has progressive course.

Why specialty drugs for Transthyretin cardiomyopathy (ATTR-CM) are hard to access internationally

Multiple TTR stabilizers and silencers are FDA-approved with cardiomyopathy indications. Vyndamax and the newer Attruby, plus Amvuttra (cardiomyopathy indication added 2025), provide options. International registration of cardiomyopathy-specific indications is uneven.

Treatments approved by the FDA

• Vyndamax (tafamidis) — FDA approval: 2019 (cardiomyopathy). Mechanism: TTR stabilizer. Route: Oral once daily. US WAC ballpark: Approximately USD 225,000 per year.
• Attruby (acoramidis) — FDA approval: 2024. Mechanism: Selective TTR stabilizer. Route: Oral twice daily. US WAC ballpark: Approximately USD 240,000 per year. Country pricing: UAE · Saudi Arabia · Qatar · Kuwait.
• Amvuttra (vutrisiran) — FDA approval: 2025 (cardiomyopathy). Mechanism: RNAi silencer (cardiomyopathy indication added 2025). Route: Subcutaneous injection every 3 months. US WAC ballpark: Approximately USD 475,000 per year. Country pricing: Saudi Arabia · Bahrain · Oman.

Cross-border pathways used for Transthyretin cardiomyopathy (ATTR-CM)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm ATTR-CM by technetium pyrophosphate scintigraphy or biopsy; exclude AL amyloidosis.
• Document TTR genotype.
• Document NYHA class, NT-proBNP, and cardiac biomarkers at baseline.
• Cardiology specialist with amyloidosis experience co-manages.
• Long-term planning for supply continuity.

Common questions

How do I choose between TTR drugs?

Choice depends on phenotype, stage, and tolerability. Your cardiologist decides.

Are these drugs available in my country?

Vyndamax is more widely registered globally; the newer agents are still rolling out.

How long does shipment take?

Five to fifteen business days from prescription receipt.

Can I switch between drugs?

Switching is feasible and sometimes indicated. We support sequential supply.

What documents are required?

Cardiologist's prescription, scintigraphy or biopsy confirmation, TTR genotype if known, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Transthyretin cardiomyopathy (ATTR-CM), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Transthyretin cardiomyopathy (ATTR-CM)

Reserved for you.